Skip to content
thestock.space

As of 6 Nov 2026, Piramal Pharma is loss-making on a trailing 12-month basis, with a net loss of ₹209 Cr, so it has no P/E ratio. The share price is ₹239.32. Sales grew 7.6% a year over 3 years. Debt is 0.72× equity. It is a small-cap company with a market cap of ₹31,736 Cr, ranked 18th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 19% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹238.80
Day high
₹240.00
Day low
₹235.12
Prev. close
₹238.63
Volume
28.5 L

Health check

1 fair · 5 to check
  • ReturnsIn line

    +19.1% over a year, better than 3 of 7 peers.

  • Price tagLoss-making

    Earnings were negative over the last 12 months.

  • GrowthUnder pressure

    Sales +7.6% a year over 3 years, but loss-making now.

  • ProfitabilityWeak

    ROCE 1.2% vs peer median 17.9%.

  • Balance sheetStretched

    Debt 0.72× equity, interest covered 0.5×, Piotroski 2 of 9.

  • Red flags3 to check

    Loss-making over the last twelve months.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹31,736 Cr, #18 of 154 in its industry by size.

Defensive

Beta 0.22 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Sep 2026: sales ₹9,779 Cr · profit ₹−209 Cr
Market cap
₹31,736 Cr
Small cap
P/E
n/a
Industry 28.7
Price to book
4.10
Peers 4.99
Dividend yield
0.00%
ROE
−2.6%
Peers 14.7%
ROCE
1.2%
Peers 17.9%
Debt to equity
0.72
Debt ₹5,873 Cr
EPS (TTM)
−₹1.58
Face value ₹10
OPM (TTM)
11.1%
Net margin −2.1%
Sales growth
+28.1%
Latest quarter vs a year ago
Profit growth
n/a
Year-ago quarter not reported
Price to sales
3.25
EV/EBITDA 34.8

Strengths and risks

Strengths

  • Quarterly sales up 28.1% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Loss-making over the last twelve months.
  • Return on equity is low at −2.6%.
  • Interest coverage of only 2.9×.

Derived automatically from reported figures. Not a recommendation.

About Piramal Pharma

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation…

Headquarters
Mumbai
Employees
7,120
Sector
Healthcare
ISIN
INE0DK501011
Website
piramalpharma.com

Price range

52 weeks

₹132.30₹243.20

Today

₹235.12₹240.00
Avg volume (3M)
63.3 L
1-year return
plus 19.1%
From 52-week high
minus 1.6%

Analyst consensus

11 analysts
Strong buyMean target ₹262.91 plus 9.9%

Target range, with today’s price

Low ₹220.00High ₹300.00

Next results expected around 27 Jan 2027

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
PPLPHARMAPiramal Pharma239.32plus 0.29%31,736–4.101.2%−2.6%12.3%7.6%–0.00%plus 19.1%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Dec 25Mar 26Jun 26Sep 26
1,9342,1402,7522,2702,617
1,8271,9442,4072,0752,268
107196344195349
5.5%9.1%12.5%8.6%13.3%
7754.417610953.7
86.289.28388.187.6
197213218224233
20.7−42−176––
−79−93.943−7.581.6
−3.4%−45.1%120.5%−830.2%93.8%
−81.7−136−8.8−69.45.6
-0.62-1.03-0.07-0.520.04

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+7.6%
ROE
−2.6%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
7,0328,1069,0618,759
–+15.3%+11.8%minus 3.3%
6,4046,9047,5667,773
6291,2031,495986
8.9%14.8%16.5%11.3%
270229194245
338447418338
677741816831
−4.9−64.8−39.7−238
−120179415−176
−55.2%90.1%78.0%−85.1%
−18617.891.1−326
––+411.4%minus 457.7%
-1.540.140.69-2.46

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
1,1931,3231,3241,327
5,5806,5886,8016,835
5,6374,7104,8565,675
2,1122,6902,6964,128
14,52315,31215,67817,965
4,4414,8165,0245,642
853566489799
41.834.944.360.8
6605043921,335
8,5279,3929,72910,128
14,52315,31215,67817,965

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
4841,0058921,653
−1,339−434−477−826
818−422−441−39
−37.1148−26788
−965−712−664−890
−481293228763
−67–−14.5−18.6

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 20.0% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you